P1533: TRIAL IN PROGRESS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PARSACLISIB IN PATIENTS WITH PRIMARY WARM AUTOIMMUNE HEMOLYTIC ANEMIA

• W. Barcellini,
• K. Butler,
• S. Moran,
• K. Bibeau,
• I. Dzhindzhikhashvili,
• S. Wei,
• U. Jäger

Affiliations

W. Barcellini

1 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

K. Butler

2 Incyte Corporation, Wilmington, DE, United States of America

S. Moran

2 Incyte Corporation, Wilmington, DE, United States of America

K. Bibeau

2 Incyte Corporation, Wilmington, DE, United States of America

I. Dzhindzhikhashvili

2 Incyte Corporation, Wilmington, DE, United States of America

S. Wei

2 Incyte Corporation, Wilmington, DE, United States of America

U. Jäger

3 Medical University of Vienna, Vienna, Austria